Rigel Pharmaceuticals Files Definitive Proxy Statement
Ticker: RIGL · Form: DEF 14A · Filed: Apr 10, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Rigel Proxy Statement filed. Vote on directors & pay. Meeting May 22.
AI Summary
Rigel Pharmaceuticals Inc. filed its definitive proxy statement (DEF 14A) on April 10, 2025, for its annual meeting on May 22, 2025. The filing outlines the company's governance and proposals for shareholders, including the election of directors and executive compensation. Rigel Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancer.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, voting matters, and executive compensation, enabling informed participation in corporate governance decisions.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing information to shareholders and does not inherently present new financial risks.
Key Players & Entities
- RIGEL PHARMACEUTICALS INC (company) — Registrant
- 0001140361-25-013250 (filing_id) — Accession Number
- 20250410 (date) — Filing Date
- 20250522 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals.
When is the Rigel Pharmaceuticals annual meeting scheduled?
The annual meeting of Rigel Pharmaceuticals is scheduled for May 22, 2025.
What is the filing date of this DEF 14A?
This Definitive Proxy Statement was filed on April 10, 2025.
What is the company's Standard Industrial Classification (SIC) code?
Rigel Pharmaceuticals Inc. has a Standard Industrial Classification code of 2834, which corresponds to Pharmaceutical Preparations.
Where is Rigel Pharmaceuticals, Inc. headquartered?
Rigel Pharmaceuticals, Inc. is headquartered at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).